Patents Examined by James H. Alstrum-Acevedo
  • Patent number: 11155592
    Abstract: PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: October 26, 2021
    Assignee: Eli Lilly and Company
    Inventors: Daniel Anthony Briere, Daniel Christopher Lopes, Avinash Muppidi
  • Patent number: 11155601
    Abstract: The invention relates to a modified VWF molecule for use in the treatment of a blood coagulation disorder.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 26, 2021
    Assignee: CSL BEHRING LENGNAU AG
    Inventors: Michael Moses, Stefan Schulte, Gerhard Dickneite, Uwe Kalina, Sabine Pestel, Thomas Weimer
  • Patent number: 11155603
    Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumori-genic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: October 26, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Aleksander S. Popel, Elena V. Rosca, Jacob E. Koskimaki, Corban G. Rivera, Niranjan B. Pandey, Amir P. Tamiz
  • Patent number: 11155596
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERNX4AAX7EIL X11LPNLX16X17X18QX20 WAFIWX26LX28D. The present disclosure also relates to the use of such a PD-L1 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 26, 2021
    Assignee: AFFIBODY AB
    Inventors: Elisabet Wahlberg, Elin Gunneriusson
  • Patent number: 11154595
    Abstract: The present invention relates to a method for preventing and treating pulmonary fibrosis, comprising administering an effective amount of plasminogen to a subject.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: October 26, 2021
    Assignee: Talengen International Limited
    Inventor: Jinan Li
  • Patent number: 11154585
    Abstract: The present invention relates to an oral applicable therapeutic dosage form, in particular an orodispersible film comprising Enalapril or pharmaceutically acceptable salts thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined from 1 to 18 years of age. The present invention also provides a method of manufacturing of such a dosage form.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: October 26, 2021
    Assignee: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthymios Koutris, Vasiliki Samara, Ioanna Koutri, Anastasia Kalaskani, Lida Kalantzi, Andreas Kakouris, Amalia Diakidou, George Gotzamanis, Zaharias Georgousis, Louiza Konstanti
  • Patent number: 11155587
    Abstract: Disclosed herein is a synthetic polypeptide with “n” number of repeats of a sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. The synthetic polypeptide as disclosed herein is represented by an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5. The synthetic polypeptide of the present disclosure is used to prepare synthetic elastomeric hydrogel. Also, disclosed are the methods of preparing the synthetic polypeptide and the elastomeric hydrogel along with their uses.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: October 26, 2021
    Assignee: PANDORUM TECHNOLOGIES PRIVATE LIMITED
    Inventors: Tuhin Bhowmick, Arun Chandru Raja
  • Patent number: 11150251
    Abstract: The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation and is useful for bioprinting.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: October 19, 2021
    Assignees: Clemson University Research Foundation, MUSC Foundation for Research Development
    Inventors: Ying Mei, Jia Jia, Chung-Jen James Chou
  • Patent number: 11149061
    Abstract: A method of purifying an antifreeze protein (AFP) and methods of producing AFPs are disclosed. The method of purifying an AFP includes heating a crude AFP in an aqueous medium to a temperature and for a length of time sufficient to precipitate at least some thermally unstable proteins in the crude AFP and form a precipitate and a supernatant; and removing the precipitate from the supernatant. One method of producing an AFP includes collecting a crude source of the AFP; and purifying the AFP by the purification method. Another method of producing an AFP includes growing or culturing a host configured to express a recombinant AFP in a growth medium, and collecting a crude AFP from the host and/or the growth medium. The growth medium comprises water, a protein hydrolysate or other source of amino acids, a yeast extract, a biologically metabolizable C3-C6 polyol, and one or more phosphate salts.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: October 19, 2021
    Assignees: The Board of Trustees of the California State University, California State University, Los Angeles
    Inventor: Xin Wen
  • Patent number: 11149071
    Abstract: The present invention provides a recombinant fusion protein. The fusion protein is formed by the fusion of D2 domain of Slit2 protein and HSA protein, and the position 386 amino acid of the Slit2 protein molecule is serine.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: October 19, 2021
    Assignee: ASCLEPIUS (SUZHOU) TECHNOLOGY COMPANY GROUP CO., LTD.
    Inventors: Huashun Li, Baoyong Ren, Peng Liu
  • Patent number: 11149078
    Abstract: The application concerns tissue inhibitor of metalloproteinase 3 (TIMP-3) muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them; in particular, muteins of TIMP-3 with specific amino acid substitutions in order to introduce N-linked glycosylation sites.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: October 19, 2021
    Assignee: Amgen Inc.
    Inventors: Jason C. O'Neill, Randal R. Ketchem, Taeweon Lee, Vishnu Chintalgattu, Jennitte Leann Stevens
  • Patent number: 11141466
    Abstract: The present invention relates to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) capable of binding to blood coagulation Factor VIII (FVIII) for use in reducing the immunogenicity of Factor VIII (FVIII) wherein said recombinant polypeptide and a blood coagulation Factor VIII (FVIII) protein are co-administered to a subject suffering from a 10 blood coagulation disorder. The invention further relates to pharmaceutical compositions and kits for said use.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: October 12, 2021
    Assignee: CSL Behring Lengnau AG
    Inventors: Anne Verhagen, Sabine Pestel, Thomas Weimer, Marco Hofmann, Huy Huynh, Eugene Maraskovsky
  • Patent number: 11124542
    Abstract: Modulators of melanocortin receptors (MCR) are provided herein. An MC5R peptide ligand is represented by to Formula 1: R1-Nle4-c[Xaa5-Yaa6-(NMe)D-Nal(2?)7-Arg8-Trp9-(NMe)Zaa10]-R2. R1 can be an acetyl, a glycosylated amino acid, —CO—(CH2)nCH3, or —CO—(CH2)nCF3 with n ranging from 1 to 6. R2 can be an —CONH2, —COOH, or —CH2OH. Xaa, Yaa, and Zaa can each be a natural amino acid or an unnatural amino acid.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: September 21, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Victor J. Hruby, Minying Cai
  • Patent number: 11116816
    Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: September 14, 2021
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • Patent number: 11116868
    Abstract: The present invention refers to a composition, comprising hemoglobin or myoglobin, wherein in at least 40% of said hemoglobin or myoglobin the oxygen binding site is charged by a non-O2 ligand, and at least one further ingredient, a method for preparing said composition and the use of hemoglobin or myoglobin charged with a non-oxygen ligand for external treatment of wounds.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: September 14, 2021
    Assignee: MÖLNLYCKE HEALTH CARE AB
    Inventors: Michael Sander, Harald Potzschke
  • Patent number: 11117930
    Abstract: This invention relates to materials, such as peptides, and methods to inhibit the aggregation transcription factors, for example p53 inhibitors, p63 inhibitors and p73 inhibitors. More specifically, the invention relates to cancer chemotherapeutics. More specifically, the invention provides pharmaceutical compositions and methods of treating cancer with certain peptides.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: September 14, 2021
    Assignee: ADRX, INC.
    Inventors: Shiho Tanaka, Ashley Wright, James Treanor, Marcin Apostol
  • Patent number: 11111272
    Abstract: The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against ?4?1 binding, and have high stability under gastrointestinal conditions.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: September 7, 2021
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Larry C. Mattheakis, David Liu
  • Patent number: 11110152
    Abstract: Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are SP-A peptides and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD).
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: September 7, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Julie Ledford, Monica Kraft
  • Patent number: 11111278
    Abstract: The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: September 7, 2021
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Eric N. Olson, Rhonda S. Bassel-Duby, Catherine A. Makarewich, Benjamin R. Nelson
  • Patent number: 11103557
    Abstract: The present invention relates to a novel exenatide analogue, which is an exenatide analogue in which the first to fifteenth amino acids from the C-terminal of the amino acid sequence of exenatide are deleted and a fatty acid is conjugated. The present invention provides a short length exenatide exhibiting almost the same level of anti-diabetic effects compared with that of conventional exenatide and liraglutide, which is an anti-diabetic drug, and capable of reducing the preparation cost of exenatide.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: August 31, 2021
    Assignee: ANYGEN Co., Ltd.
    Inventors: San Ho Kim, Seon Myung Kim, Moon Young Park